arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo


 


Presented by the Johns Hopkins University School of Medicine.

Supported by an educational grant from Allergan Inc.


OVERVIEW

Despite the critical role of vascular endothelial growth factor (VEGF) inhibitors in managing patients with diabetic macular edema (DME), up to half of patients fail to respond or experience inadequate response to first-line monotherapy with these agents and remain at high risk for vision loss due to persistent edema. Increasing evidence has demonstrated the significance of inflammation, in addition to angiogenesis, as part of the underlying pathogenesis of DME. Steroids and steroid implants, which provide sustained anti-inflammatory activity, offer an efficacious treatment option for these patients, particularly for those who are refractory to anti-VEGF therapies and who experience chronic DME. In order to develop and provide individualized, efficacious treatment plans for patients with DME, considering both anti-VEGF agents and steroids, ophthalmology healthcare providers (HCPs) require the most up-to-date clinical information to inform treatment decision-making.

GOAL

The goal of this activity is to provide ophthalmology HCPs with comprehensive education that will inform DME treatment decision-making, including the rationale for and mechanism of anti-inflammatory treatments for DME, strategies to identify patients who are likely to benefit from such treatment options, as well as strategies to develop, implement, manage individualized treatment paradigms.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists and comprehensive ophthalmologists. No prerequisites required.

LEARNING OBJECTIVES

After participating in this activity, the participant will demonstrate the ability to:

  • DESCRIBE the inflammatory mechanisms that contribute to DME pathology and serve as a target for treatment.
  • EVALUATE the efficacy, safety and clinical utility of steroids as part of treatment paradigms for DME.
  • RECOGNIZE the importance of resolving residual macular edema on attaining gains in visual acuity.
  • PROPOSE patient-specific DME treatment plans that appropriately incorporate steroid therapies.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

CME INFORMATION

ACCREDITATION STATEMENT
accme_logoThe Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category I Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

After reviewing this online activity, participants may receive a certificate by receiving a score of 70% or higher on the CME test and completing an evaluation. A certificate of participation will be available online immediately following successful completion of the activity.

The estimated time to complete this educational activity: 60 minutes.

Release date: December 17, 2018.  Expiration date: December 17, 2019.

PARTICIPATING FACULTY
J. Fernando Arevalo, MD, FACS (Chair)
Edmund F. and Virginia B. Ball Professor of Ophthalmology
The Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, Maryland

Peter A. Campochiaro, MD
Eccles Professor of Ophthalmology and Neuroscience
The Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, Maryland

Andrew A. Moshfeghi, MD, MBA
Director, Clinical Trials Unit and Retina Fellowship
Associate Professor, Ophthalmology
USC Roski Eye Institute, Retina Service
Keck School of Medicine
University of Southern California
Los Angeles, California

DISCLOSURE POLICIES
Policy on Speaker and Provider Disclosure
It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies that will identify and resolve conflicts of interest prior to this educational activity. Detailed disclosures will be made prior to presentation of the educational activity.

Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME.

The following relationships have been reported for this activity:
Planners
J. Fernando Arevalo, MD, FACS reports receiving grant/research support from Topcon Positioning Systems, Inc.; receiving royalties from Springer Science + Business Media, LLC; serving as a consultant for Allergan, Bayer AG, DORC Dutch Ophthalmic Research Center (International) BV, Mallinckrodt LLC, and Turing Pharmaceuticals LLC.

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Speakers
Peter A. Campochiaro, MD reports serving as a principal investigator for Aerpio Therapeutics, Allergan Inc, AsclepiX Therapeutics, Clearside Biomedical, Genentech, Inc., Genzyme Corporation, Oxford BioMedica, Regeneron Pharmaceuticals, and REGENXBIO, Inc.; serving as a consultant for Aerpio Therapeutics, Applied Genetic Technologies, Allergan Inc, Allegro, AsclepiX Therapeutics, Exonate, Genentech, Inc., Graybug Vision, Inc., Merck & Co, Inc., Novartis AG, and RXi Pharmaceuticals; and having ownership interest in Graybug Vision, Inc.

Andrew A. Moshfeghi, MD, MBA reports serving as a principal investigator for Regeneron Pharmaceuticals and Roche; serving as a consultant for Allergan, Inc., Allegro Ophthalmics LLC, Clearside EyePoint Pharmaceuticals, Novartis AG, Roche, Regeneron Pharmaceuticals, Valeant Pharmaceuticals, Visunex Medical Systems, Inc.; and having ownership interest in OptiSTENT, Inc., Pr3vnt, and Visunex Medical Systems Inc.

No other faculty members have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

DISCLAIMER

The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANTS

I certify that I am attending a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person's health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc), in any electronic messaging program or through any portable electronic device.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only.”

For CME Questions, please contact the CME Office at 410-955-2959 or e-mail cmenet@jhmi.edu. For CME Certificates, please call 410-502-9634.

Johns Hopkins University School of Medicine Office of Continuing Medical Education
Turner 20/720 Rutland Avenue
Baltimore, Maryland
21205-2195

Reviewed & Approved by:
General Counsel, Johns Hopkins Medicine (4/1/03)
(Updated 4/09 and 3/14)

HARDWARE & SOFTWARE REQUIREMENTS

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

ACTIVITY

Instructions
The following is an archived live symposium designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 4 sections: an unaccredited preassessment, the archived live symposium activity, a CME postassessment, and evaluation. All 4 sections must be completed to receive CME credit. A certificate of participation will be available online immediately following successful completion of the activity.


TABLE OF CONTENTS
Preassessment

Evolving Insights into the Inflammatory Pathology of DME
Andrew A. Moshfeghi, MD, MBA

Clinical Implications of the Latest Evidence: Evaluating the Role of Steroids
J. Fernando Arevalo, MD, FACS

Attaining Treatment Goals in DME: Resolving Edema and Improving Visual Acuity
Peter A. Campochiaro, MD

Implementing Evidence into Practice: Patient Cases
Peter A. Campochiaro, MD

Closing Remarks
J. Fernando Arevalo, MD, FACS

Postassessment and Evaluation

This activity was developed in collaboration with ASiM.

procced to pretest
footer